Skip to main content

Status Epilepticus

7
Pipeline Programs
6
Companies
10
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
1
2
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Marinus Pharmaceuticals
ZTALMYApproved
ganaxolone
Marinus Pharmaceuticals
Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]oral2022
953K Part D

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Marinus Pharmaceuticals
3 programs
2
1
1
GanaxolonePhase 31 trial
IV GanaxolonePhase 21 trial
IV Ganaxolone activePhase 21 trial
Active Trials
NCT05757544Withdrawn0Est. Feb 2026
NCT03350035Completed17Est. Sep 2019
NCT04391569Completed100Est. Apr 2024
Pfizer
PfizerNEW YORK, NY
1 program
1
LorazepamPhase 32 trials
Active Trials
NCT03905798Completed206Est. Nov 2023
NCT02239380Completed26Est. Aug 2016
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
1
1
lorazepam or diazepamPhase 2/31 trial
lorazepamPhase 11 trial
Active Trials
NCT00114569Completed69Est. Feb 2009
NCT00621478Completed259Est. May 2012
Verona Pharma
Verona PharmaUK - London
2 programs
KetamineN/A1 trial
KetaminePHASE_31 trial
Active Trials
NCT05756621Recruiting80Est. Sep 2025
NCT02431663Terminated57Est. Mar 2020
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
levetiracetamPHASE_21 trial
Active Trials
NCT00362141Unknown12Est. Apr 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Marinus PharmaceuticalsGanaxolone
Verona PharmaKetamine
PfizerLorazepam
Human BioScienceslorazepam or diazepam
Marinus PharmaceuticalsIV Ganaxolone
Marinus PharmaceuticalsIV Ganaxolone active
UCB Pharmalevetiracetam
Human BioScienceslorazepam
Verona PharmaKetamine
PfizerLorazepam

Clinical Trials (10)

Total enrollment: 826 patients across 10 trials

NCT04391569Marinus PharmaceuticalsGanaxolone

Randomized Therapy In Status Epilepticus

Start: Dec 2020Est. completion: Apr 2024100 patients
Phase 3Completed
NCT02431663Verona PharmaKetamine

Ketamine in Refractory Convulsive Status Epilepticus

Start: Apr 2015Est. completion: Mar 202057 patients
Phase 3Terminated
NCT02239380PfizerLorazepam

Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan

Start: Nov 2014Est. completion: Aug 201626 patients
Phase 3Completed
NCT00621478Human BioScienceslorazepam or diazepam

Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)

Start: Feb 2008Est. completion: May 2012259 patients
Phase 2/3Completed
NCT05757544Marinus PharmaceuticalsIV Ganaxolone

Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)

Start: Apr 2023Est. completion: Feb 20260
Phase 2Withdrawn
NCT03350035Marinus PharmaceuticalsIV Ganaxolone active

Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

Start: Feb 2018Est. completion: Sep 201917 patients
Phase 2Completed
NCT00362141UCB Pharmalevetiracetam

Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus

Start: Oct 2006Est. completion: Apr 200812 patients
Phase 2Unknown
NCT00114569Human BioScienceslorazepam

Lorazepam for the Treatment of Status Epilepticus in Children

Start: Mar 2005Est. completion: Feb 200969 patients
Phase 1Completed
NCT05756621Verona PharmaKetamine

Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest

Start: Jan 2022Est. completion: Sep 202580 patients
N/ARecruiting
NCT03905798PfizerLorazepam

LORA-PITA IV General Investigation

Start: Nov 2019Est. completion: Nov 2023206 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 826 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.